HC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price

Monopar Therapeutics (NASDAQ:MNPR) had its price objective boosted by HC Wainwright from $105.00 to $125.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 9.70% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. BTIG Research raised their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday. Chardan Capital restated a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research report on Monday, March 30th. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research note on Tuesday, June 2nd. Finally, Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Three investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Monopar Therapeutics currently has a consensus rating of “Buy” and an average target price of $110.42.

Monopar Therapeutics Stock Performance

Shares of MNPR stock traded up $0.38 on Wednesday, reaching $113.95. The stock had a trading volume of 130,595 shares, compared to its average volume of 209,874. The stock has a market cap of $763.32 million, a P/E ratio of -59.34 and a beta of 1.46. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $116.64. The company has a 50 day simple moving average of $77.57 and a 200 day simple moving average of $65.75.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.41. On average, equities research analysts anticipate that Monopar Therapeutics will post -2.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE grew its position in shares of Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics in the 1st quarter worth approximately $250,000. Siren L.L.C. boosted its stake in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after purchasing an additional 57,820 shares during the period. Finally, Sei Investments Co. boosted its stake in Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares during the period. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.